Last updated: February 20, 2026
What are the primary suppliers of Tasmar (Tolcapone)?
Tasmar (generic name: tolcapone) is a catechol-O-methyltransferase (COMT) inhibitor used alongside levodopa and carbidopa for Parkinson’s disease management. The drug's production landscape has shifted significantly since its original commercial release, primarily due to safety concerns related to hepatotoxicity.
Which companies manufacture or supply Tasmar (Tolcapone)?
Original Manufacturer
- Novartis: Developed and marketed Tasmar (Tolcapone) globally after acquiring it from Roche.
Current Supply Landscape
- As of 2023, Novartis remains the primary and, in many regions, the only active licensed producer of Tasmar.
- Other pharmaceutical entities do not currently manufacture or distribute licensed Tasmar formulations due to safety concerns and regulatory restrictions.
Regulatory and Market Context
- In the United States, the FDA approved Tasmar in 1997 but later issued a black box warning in 2011 citing hepatotoxicity risks. This led to significant restrictions and a decline in availability.
- The European Medicines Agency (EMA) withdrew marketing authorization for Tasmar in the European Union in 2012, citing post-marketing safety data.
- Despite withdrawal or restrictions in several markets, some manufacturers still supply the drug under a restricted or monitored basis, primarily in regions with less stringent regulatory oversight.
Alternative Suppliers and Formulations
- Due to safety concerns, synthetic or import-only options are sometimes used in research settings with import permits but are rarely available commercially outside of licensed markets.
Supply channels and sourcing considerations
- Official channels: Novartis active licensing in select markets.
- Generic or alternative: No widely available generic formulations due to the drug’s safety profile and limited market approval.
- Importation: Restricted and subject to regulatory approval in many countries.
Key facts
| Aspect |
Details |
| Manufacturer |
Novartis |
| Regulatory status (US) |
Approved with black box warning (FDA, 2011) |
| Regulatory status (EU) |
Withdrawn (EMA, 2012) |
| Alternative sources |
Limited; mainly research-use imports or compounded formulations |
Summary
Novartis is the primary licensed supplier of Tasmar, with significant market withdrawals in certain regions owing to safety concerns. Limited or no generic suppliers exist officially, and supply is constrained by regulatory and safety considerations. Buyers must verify regional authorization and safety protocols before sourcing.
Key Takeaways
- Novartis remains the primary supplier of licensed Tasmar.
- Regulatory restrictions have significantly limited market availability.
- No prominent generic or alternative suppliers currently distribute Tasmar widely.
- Safety concerns have led to withdrawal or restricted approvals in multiple jurisdictions.
- Importation for research may be possible with proper regulatory compliance.
FAQs
1. Can I buy Tasmar directly from Novartis?
Tasmar is marketed and supplied by Novartis in specific regions. Consumers should consult local healthcare providers or authorized distributors for availability.
2. Are there generic versions of Tasmar available?
No, generic formulations are not available due to the safety profile of tolcapone and regulatory restrictions.
3. Is Tasmar still approved in the US?
Yes, but it carries a black box warning, and its use is limited to cases where other treatments are inadequate, with strict monitoring.
4. What are the safety concerns related to Tasmar?
Hepatotoxicity is the primary concern, leading to regulatory restrictions and market withdrawals in many regions.
5. Can Tasmar be imported for personal use?
Importation is generally restricted to research or investigational purposes, requiring proper licensing and compliance with local regulations.
References
- U.S. Food and Drug Administration. (2011). Black Box Warning—Tolcapone. FDA.
- European Medicines Agency. (2012). Market withdrawal of Tasmar. EMA.
- Novartis. (2022). Product Information: Tasmar. Novartis Pharmaceuticals.
- National Institutes of Health. (2020). Parkinson's Disease Treatment Options. NIH.
- World Health Organization. (2019). Guidelines on drug safety and regulation. WHO.
